Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (16221)	3/2/1998 3:41:00 PM
From: Henry Niman	Respond to of 32384

Here's another cancer report implicating complexes involving transcription factors: Monday March 2 1:09 PM EST New Gene Linked To Breast, Lung Cancer NEW YORK (Reuters) -- A newly discovered gene is associated with the development of both breast and lung cancer, according to a multinational team of researchers. The gene, called BAP1, produces an enzyme that helps control levels of BRCA1, the gene linked to hereditary breast cancer. The discovery may have "major implications for the treatment of breast and lung cancers" according to a statement from the Philadelphia-based Wistar Institute, which sponsored the research. "BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway," reported senior investigator Dr. Frank J. Rauscher III, of The Wistar Institute. "BAP1 and BRCA1 form a complex (within cells) and this regulates the stability of BRCA1," Rauscher said in an interview with Reuters. Mutations in either BAP1 or BRCA1 lead to instability and the possibility of the development of cancer, he said. BAP1, which stands for "BRCA1-associated protein," is located on human chromosome 3p21.3. The discovery of BAP1 may lead to the development of new anticancer therapies. Because "BAP1 is an enzyme that regulates the stability of the BRCA1 protein... it can be very easily targeted with drugs," said Rauscher. "So the possibility is that a drug could be designed against this enzymatic activity." Both BAP1 and BRCA1 are expressed in breast cancers that develop in laboratory mice, and mutations in BAP1 are found in human lung cancer cells. The finding is reported in the current issue of the journal Oncogene. SOURCE: Oncogene (1998;16:1097-1112) Monday March 2 1:09 PM EST New Gene Linked To Breast, Lung Cancer NEW YORK (Reuters) -- A newly discovered gene is associated with the development of both breast and lung cancer, according to a multinational team of researchers. The gene, called BAP1, produces an enzyme that helps control levels of BRCA1, the gene linked to hereditary breast cancer. The discovery may have "major implications for the treatment of breast and lung cancers" according to a statement from the Philadelphia-based Wistar Institute, which sponsored the research. "BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway," reported senior investigator Dr. Frank J. Rauscher III, of The Wistar Institute. "BAP1 and BRCA1 form a complex (within cells) and this regulates the stability of BRCA1," Rauscher said in an interview with Reuters. Mutations in either BAP1 or BRCA1 lead to instability and the possibility of the development of cancer, he said. BAP1, which stands for "BRCA1-associated protein," is located on human chromosome 3p21.3. The discovery of BAP1 may lead to the development of new anticancer therapies. Because "BAP1 is an enzyme that regulates the stability of the BRCA1 protein... it can be very easily targeted with drugs," said Rauscher. "So the possibility is that a drug could be designed against this enzymatic activity." Both BAP1 and BRCA1 are expressed in breast cancers that develop in laboratory mice, and mutations in BAP1 are found in human lung cancer cells. The finding is reported in the current issue of the journal Oncogene. SOURCE: Oncogene (1998;16:1097-1112)